glp-1 receptor agonists for type 2 diabetes Clinical Focus on in Mellitus GLP-1 Receptor Agonists as Treatments

Groop PH, Dandona P, Phillip M et al (2020) Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials

Zhang X, Wang M, Wang X, et al

Genistein enhances the secretion of glucagon-like peptide-1 (GLP-1) via downregulation of inflammatory responses

These agents have several practical benefits for patients including promotion of weight loss, fewer needlesticks, ease of administration, and lower risk of hypoglycemia

However, all patients with a history of depression were excluded from these studies, and none of them reported the results of psychiatric outcomes